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Abstract
There is currently no accepted classification of autosomal recessive cerebellar ataxias, a group of disorders characterized
by important genetic heterogeneity and complex phenotypes. The objective of this task force was to build a consensus on
the classification of autosomal recessive ataxias in order to develop a general approach to a patient presenting with ataxia,
organize disorders according to clinical presentation, and define this field of research by identifying common pathogenic
molecular mechanisms in these disorders. The work of this task force was based on a previously published systematic
scoping review of the literature that identified autosomal recessive disorders characterized primarily by cerebellar motor
dysfunction and cerebellar degeneration. The task force regrouped 12 international ataxia experts who decided on general
orientation and specific issues. We identified 59 disorders that are classified as primary autosomal recessive cerebellar
ataxias. For each of these disorders, we present geographical and ethnical specificities along with distinctive clinical and
imagery features. These primary recessive ataxias were organized in a clinical and a pathophysiological classification, and
we present a general clinical approach to the patient presenting with ataxia. We also identified a list of 48 complex
multisystem disorders that are associated with ataxia and should be included in the differential diagnosis of autosomal
recessive ataxias. This classification is the result of a consensus among a panel of international experts, and it promotes a
unified understanding of autosomal recessive cerebellar disorders for clinicians and researchers.
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Introduction
The classification of hereditary ataxias represents a significant
challenge due to the large number of neurological and meta-
bolic diseases that present with cerebellar dysfunction and the
phenotypic heterogeneity in known genetically defined disor-
ders. Indeed, ataxia is a presenting feature in degenerative
disorders that target mainly the cerebellum, but it may be
present in hereditary spastic paraplegias, inborn errors of me-
tabolism, and various encephalopathies. Proper classification
and phenotypic understanding is of primary importance in this
field where the high prevalence of repeat expansion disorders,
which are not adequately covered by the next-generation se-
quencing (NGS) techniques [1, 2], precludes NGS as a first
diagnostic step and requires phenotypic evaluation to perform
custom gene testing when applicable. Nevertheless, autoso-
mal recessive cerebellar ataxias have remained an ill-defined
and disorganized group of disorders for two main reasons.
First, unlike the dominant ataxias that have been organized
with a numerical naming system, recessive disorders present-
ing with ataxia have been named in a highly heterogeneous
manner according to clinical features, physicians’ surname, or
regions of high prevalence. Second, several recessive
multisystemic or complex metabolic disorders present with
ataxia, such that it is difficult to properly circumscribe this
group of disorders and classify it in a meaningful way for both
clinicians and researchers. Hence, the Society for Research on
the Cerebellum and Ataxias (SRCA) Task Force on the
Classification of Recessive Cerebellar Ataxias was created in
2016 to regroup a panel of international ataxia experts in order
to propose a classification relevant to clinical practice and
researchers. As a first step, we undertook a systematic scoping
review of the literature to identify all recessive disorders pre-
senting with ataxia, select those in which cerebellar degener-
ation was a core feature, and propose a first classification. This
systematic scoping review has been previously published [3]
and served as the basis for the current work.
Recently, the Movement Disorder Society Task Force on
Classification and Nomenclature of Genetic Movement
Disorders proposed a revised naming system based on the
gene name associated with a phenotypical prefix. They pre-
sented a list of 92 gene-defined recessive disorders associated
with ataxia for which this naming system would be applied
and an exhaustive list of disorders that may occasionally pres-
ent with ataxia [4]. This represents a useful reference for in-
terpretation of NGS results. However, in a significant number
of listed disorders, the cerebellum is only one of the many
affected organs in multisystemic and metabolic disorders.
For example, maple syrup urine disease, caused by
BCKDHB mutations, and congenital disorders of glycosyla-
tion 1a, 1c, and 1q have been included. These disorders are
inborn errors of metabolism characterized by developmental
delay, hypotonia, and metabolic defects, and ataxia is only
mild, found in a minority of patients, or present solely during
episodes of metabolic decompensation. Hence, there remains
a need for a classification system that focuses on disorders
affecting primarily the cerebellum and organizes clinical and
paraclinical information to promote an understanding of cer-
ebellar disorders useful not only to ataxia experts but also to
general neurologists, learners, patients, and researchers.
The objective of this task force was to build a consensus on
the classification of autosomal recessive ataxias in order to
develop a general approach to a patient presenting with ataxia,
organize disorders according to clinical presentation, and de-
fine this field of research by identifying common pathophys-
iological mechanisms in recessive disorders presenting with
ataxia. This aims at bringing together clinicians and re-
searchers to promote a common understanding of recessive
cerebellar disorders in order to advance research and improve
patient care.
Materials and Methods
The first step was to identify all recessive disorders presenting
with ataxia. Recessive cerebellar ataxias were defined as dis-
orders with autosomal recessive inheritance characterized by a
cerebellar motor syndrome of gait ataxia, dysmetria,
adiadochokinesia, nystagmus, and dysarthria associated with
cerebellar degeneration as demonstrated by imagery or pathol-
ogy. A pathogenic mutation had to be identified in at least two
independent families for a specific gene to be included. Purely
malformative disorders were excluded, and disorders with
complex phenotypes where ataxia is a secondary or late fea-
ture were also excluded. We conducted a systematic scoping
review of the literature to identify relevant reports. The meth-
odology and results of this systematic review have been pub-
lished previously [3]. In the first publication, this review pro-
cess had allowed the identification of 2354 records and was
current as of September 2016. The literature search was up-
dated and is current as of October 2018.
The second step was to regroup a panel of 12 international
ataxia experts to create a logical classification system and
build a consensus. Ataxia experts were identified from various
geographical regions and areas of expertise within the field of
ataxias, ensuring proper representation of regional differences
in prevalence and clinical approach to ataxias. Discussions
spanned over 2 years, included meetings at two SRCA inter-
national conferences, and concerned general orientation, clin-
ical approach, specific disorders, classification issues, and re-
gional specificities. The first author (MB) reviewed identified
records for inclusion, extracted clinical, epidemiological, and
molecular data to build the classifications and wrote the text
integrating all authors’ input and comments. All authors ap-
proved the final manuscript and list of included disorders.
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Results
The final list of included autosomal recessive cerebellar
ataxias is presented in Table 1 and includes 59 primary reces-
sive ataxias, which regroup 15 disorders that are more preva-
lent and widely distributed and 44 disorders that are less fre-
quent and reported only in certain populations or few families.
Because ethnic and regional specificities are an essential ele-
ment to consider in the appraisal of a patient with a recessive
ataxia, areas where the disorder has been reported to date are
listed. Metabolic or mitochondrial disorders where ataxia is
only a secondary nonspecific finding in a multisystemic phe-
notype were excluded, as cerebellar pathology is not central in
these disorders. However, clinicians must bear in mind that
some of these disorders may present with a milder juvenile or
adult onset phenotype where cerebellar ataxia may predomi-
nate, for example, in Niemann-Pick disease type C, Tay-Sachs
disease, sialic acid storage disorders, congenital disorders of
glycosylation, and Zellweger spectrum disorders. As some of
these metabolic disorders may benefit from early treatment,
clinicians must keep a high index of suspicion to test for these
disorders, and they should be included in large NGS gene
panels for ataxia. These and other complex disorders that
may occasionally present with ataxia are presented in
Table 2. This second list is not exhaustive and presents only
the main or most frequent disorders occasionally associated
with ataxia. Disorders in which the cerebellar phenotype is not
clearly established have been excluded.
Clinical Approach to a Patient Presenting with Ataxia
1. The first step in evaluating a patient with ataxia is to
perform a detailed clinical evaluation that includes a clin-
ical history, a family history, a targeted neurological and
systemic physical evaluation, and relevant paraclinical
tests. The temporal course is a central element in deter-
mining the underlying etiology. Indeed, a chronic pro-
gressive evolution over months to years, without trauma
or toxin exposure, is suggestive of a hereditary disorder,
whereas acute or subacute onset points towards an ac-
quired etiology. A clinical history and physical examina-
tion are essential to assess the severity of the cerebellar
syndrome and the presence of associated neurological
features or systemic involvement. Headache, fever, or an
associated autoimmune disorder should prompt the con-
sideration of acquired etiologies. A detailed family history
should be obtained to search for relatives with similar
symptomatology. Laboratory tests may be useful to rule
out acquired causes or as biomarkers for certain disorders.
Neuroimaging, preferably with magnetic resonance imag-
ing, is an essential tool to evaluate the presence of cere-
bellar atrophy or signal anomalies, to search for associat-
ed pontine atrophy, and to rule out space-occupying
lesions. Electromyography and nerve conduction studies
can prove the presence of clinically suspected or subclin-
ical neuropathy and provide evidence of associated
myopathy.
2. Following the clinical assessment, one should verify that
acquired and treatable causes for ataxia have been exclud-
ed. These include vascular disease, trauma, infection, pri-
mary or metastatic tumor, excess alcohol consumption,
vitamin deficiency, Creutzfeldt-Jakob disease, and
immune-mediated cerebellar ataxias such asmultiple scle-
rosis, gluten ataxia, anti-GAD (glutamic acid decarboxyl-
ase) ataxia, and paraneoplastic cerebellar degenerations.
Clinical evaluation should reveal previous exposure to
toxins or traumatic injuries, along with specific signs
and symptoms suggestive of infectious, vascular, or met-
astatic disease. Laboratory tests are useful to identify vi-
tamin deficiencies or autoimmune conditions.
Specifically, testing for antibodies involved in
paraneoplastic or autoimmune cerebellar degeneration
may be particularly useful for patients with a subacute
progression, older age at onset, and absence of family
history. The paraneoplastic antibodies most associated
with cerebellar degeneration are anti-Yo, anti-Hu, anti-
Tr, and anti-mGluR1 antibodies; the tumors most often
involved are breast and gynecological tumors, Hodgkin
lymphoma, and small-cell lung carcinoma [218]. Large
paraneoplastic autoantibody panels are now available
and may reduce the delay associated with serial testing.
3. Once acquired causes have been ruled out, a genetic eti-
ology may be considered, especially in the presence of a
positive family history, early onset, chronic progressive
course, or with a set of clinical signs and symptoms that
is reminiscent of a well-described genetic disorder. One
should bear in mind that a negative family history does
not rule out a genetic cause, and sporadic cases may be
due to recessive or mitochondrial inheritance, de novo
mutations, genetic anticipation, incomplete penetrance,
variability in disease expression, paternity error, gonadic
mosaicism, or incomplete phenotyping of family mem-
bers. Indeed, recessive disorders may appear as sporadic
in small kindred or with incomplete family history. In
other cases, a complete family history should allow iden-
tification of the mode of transmission.
4. If autosomal recessive inheritance is suspected, the next
step in clinical evaluation is to consider age at onset and
clinical signs and symptoms to evaluate if the clinical
picture is reminiscent of a well-described disorder.
Presentation in infancy suggests ataxia telangiectasia or
autosomal recessive ataxia of Charlevoix-Saguenay.
Childhood or teenage onset should raise the suspicion
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Table 1 Primary autosomal recessive cerebellar ataxias
MDS nomenclature1
or gene name




ATX-FXN FRDA 229300 Most prevalent in populations
of European descent, Middle
East, and North Africa;
absent in Far East
populations
Bilateral Babinski sign, square-wave
jerks, scoliosis, hypertrophic
cardiomyopathy, sensory involvement,
teenage onset, spinal cord atrophy, ab-
sence of cerebellar atrophy
[5, 6]
ATX-ATM AT 208900 Second most common cause of
recessive ataxia worldwide,




predisposition for cancer, dystonia,
myoclonus, choreoathetosis, tremor,
elevation of α-fetoprotein, infantile
onset, cerebellar atrophy
[7–9]
ATX-APTX AOA1/EAOH 208920 Most prevalent in Japan;










ATX-SETX AOA2 606002 Worldwide, second most
prevalent in Eastern France
Axonal sensorimotor polyneuropathy,
pyramidal signs, oculomotor apraxia,
head tremor, chorea, dystonia,
elevation of α-fetoprotein, teenage
onset, cerebellar atrophy
[13–15]
ATX/HSP-SACS ARSACS 270550 Worldwide Spastic paraparesis, retinal striation with
thickened retinal nerve fibers,
sensorimotor neuropathy, pes cavus,
infantile or childhood onset, anterior
superior cerebellar atrophy, occasional
T2-weighted linear hypointensities in
pons
[16, 17]




Cerebellar and sensory ataxia, dysarthria,
progressive external ophthalmoplegia,
myoclonus, epilepsy, myopathy,
migraine, variable age at onset, signal
abnormalities in the cerebellum and
thalamus
[18–20]
ATX-SYNE1 ARCA1 610743 Worldwide Pure cerebellar ataxia with occasional
upper and/or lower motor neuron
involvement, cognitive impairment,
late onset, cerebellar atrophy
[21–23]
HSP/ATX-SPG7 SPG7 607259 Described worldwide, frequent
in Europe
Spasticity, pyramidal signs, optic
neuropathy, ptosis, ophthalmoparesis,













ATX-ANO10 ARCA3 613728 European descent, Middle East,
West Indies, Japan
Pure cerebellar ataxia with occasional
upper motor neuron signs, cognitive
impairment, epilepsy, nystagmus,
teenage or adult onset, cerebellar
atrophy
[28–30]
ATX-TTPA AVED 277460 Worldwide, high prevalence
around Mediterranean sea
Dorsal column involvement, areflexia,
retinitis pigmentosa, head titubation,
low serum vitamin E, skeletal
deformities, teenage onset, spinal cord
atrophy, occasional cerebellar atrophy
[31–33]




Alternate nomenclature2 OMIM Geographic specificities Additional clinical clues and
neuroimaging findings
References
ATX-CYP27A1 CTX 213700 Worldwide Dementia, pyramidal signs, epilepsy,
tendon xanthomas, atherosclerosis,
cataracts, diarrhea, elevated serum
cholestanol, polyneuropathy,
childhood to adult onset, variable
cerebellar atrophy, cerebellar or
cerebral white matter anomalies
[34–36]
ATX-SIL1 MSS 248800 Worldwide Cataracts, intellectual disability,





IOSCA/MTDPS7 271245 Described worldwide, highly
prevalent in Finland




liver involvement, infantile onset,
atrophy of the brainstem and
cerebellum
[39, 40]
Rare ataxias or described only in few families
ATX-ABHD12 PHARC 612674 Europe, USA, Middle East,
Algeria
Demyelinating sensorimotor neuropathy,
pes cavus, cataracts, hearing loss,
retinitis pigmentosa, teenage onset,
cerebellar atrophy
[41, 42]
ATX/HSP-AFG3L2 SPAX5 614487 Colombia, Saudi Arabia Ataxia, spasticity, oculomotor apraxia,
myoclonic epilepsy, neuropathy,
extrapyramidal involvement, optic
atrophy, severe cases with
developmental regression,
microcephaly, hypsarrhythmia and
intractable epilepsy, infantile to
childhood onset, cerebellar atrophy
[43, 44]




dystonia, neonatal or infantile onset,
cerebellar hypoplasia
[45, 46]






HSP/ATX-CAPN1 SPG76 616907 Europe, Middle East, Brazil,
Japan, Punjab
Pyramidal signs, pes cavus, dysarthria,
ataxia, slow saccades, cognitive









occasional mild spasticity, childhood
to adult onset, T2 hypersignal in




COA7 MC4D, SCAN3 220110 Italy, Japan Sensorimotor neuropathy, hyporeflexia,
mild cognitive impairment, elevated
serum creatine kinase, elevated lactate
and pyruvate, ragged red fibers,






220110 Turkey Growth retardation, pyramidal signs,
sensory neuropathy, extrapyramidal
[55, 56]




Alternate nomenclature2 OMIM Geographic specificities Additional clinical clues and
neuroimaging findings
References
features, elevation of blood lactate,
childhood or teenage onset, cerebellar
atrophy
ATX-CWF19L1 SCAR17 616127 Turkey, Netherlands Intellectual disability, congenital to
infantile onset, cerebellar atrophy
[57, 58]
HSP/ATX-CYP7B1 SPG5A 270800 Worldwide, prevalent in
Europe
Pyramidal signs, dorsal column sensory
deficits, urge incontinence or voiding,
childhood or teenage onset, white
matter lesions
[59, 60]
ATX/HSP-DARS2 LBSL 611105 Worldwide, high carrier rate in
Finland
Pyramidal signs, dorsal column
dysfunction, axonal neuropathy, tremor,
cerebral lactic acidosis, seizures, infantile
to adult onset, signal abnormalities in
cerebral white matter and specific
brainstem and spinal cord tracts
[61, 62]
ATX-DNAJC19 DCMA/MGCA5 610198 Canadian Hutterite population,
Finland, Turkey
Dilated cardiomyopathy, nonprogressive
cerebellar ataxia, intellectual disability,
testicular dysgenesis, anemia,
increased urinary 3-methylglutaconic
acid, infantile onset, progressive cere-
bellar atrophy
[63–65]
HSP/ATX-GBA2 SPG46 614409 Tunisia, Cyprus, Italy, Norway Pyramidal signs, spastic dysarthria,
cognitive impairment, hearing loss,
cataracts, urge incontinence, axonal
sensorimotor neuropathy, childhood
onset, cerebellar and cerebral atrophy,
thin corpus callosum
[66, 67]
GDAP2 – – Belgium, Dutchland, Egypt Pyramidal signs, cognitive impairment,





608804 Worldwide Nystagmus, hypotonia progressing to
spastic tetraparesis, developmental






614018 North Sea region Areflexia, myoclonic seizures, scoliosis,
late cognitive impairment, axonal
sensory neuropathy and anterior horn
cell involvement, raised creatine
kinase, infantile onset, occasional
cerebellar atrophy
[71, 72]
ATX-GRID2 SCAR18 616204 Middle East, Mexico, Morocco Tonic upgaze, vertical nystagmus,
oculomotor apraxia, intellectual
disability, developmental delay,
hypotonia, infantile onset, cerebellar
atrophy; possible autosomal dominant
transmission
[73, 74]
GRM1 SCAR13 614831 Roma ethnic group in Bulgaria Developmental delay, intellectual
disability, occasional pyramidal signs,
short stature, seizures, congenital
onset, cerebellar atrophy; allelic with
SCA44
[75, 76]
ATX-GRN CLN11 614706 Italy, Portugal, Brazil Myoclonic epilepsy, retinopathy,
dementia, adult onset, cerebellar
atrophy
[77, 78]
ATX-ITPR1 Gillespie syndrome 206700 Brazil, Europe, North Africa,
Middle East, Asia,
Caribbean Islands
Autosomal recessive and dominant
transmission. Nonprogressive
cerebellar ataxia, iris hypoplasia,
hypotonia, intellectual disability, facial
dysmorphism, neonatal onset,
progressive cerebellar atrophy; allelic
with SCA15 and SCA29
[79, 80]




Alternate nomenclature2 OMIM Geographic specificities Additional clinical clues and
neuroimaging findings
References
HSP/ATX-KIF1C SPAX2/SPG58 611302 Palestine, Morocco, Turkey,
Germany
Spastic paraparesis with pyramidal signs,
tremor, childhood or teenage onset, T2
hyperintensity in internal capsules,
parietal and occipital white matter,









intellectual disability, tubulopathy and
electrolyte imbalance, hypotonia
progressing to spasticity, infantile
onset, cerebellar hypoplasia, signal




236792 Worldwide Developmental delay, macrocephaly,
hypotonia, elevated levels of
L-2-hydroxyglutaric acid, infantile to
adult onset, subcortical white matter,
dentate nucleus and basal ganglia sig-
nal anomalies, cerebellar atrophy
[86, 87]








MTPAP SPAX4 613672 Amish families Pyramidal signs, optic atrophy, sensibility
to ionizing radiations, developmental
delay, cognitive impairment, growth
failure, infantile onset
[90, 91]
ATX-PEX10 PBD 6B or ZSD 614871 Caucasians, Japan Axonal motor or sensorimotor
neuropathy, variable cognitive
impairment, nystagmus, hypo or
hyperreflexia, childhood to adolescent
onset, cerebellar atrophy
[92, 93]
ATX-PMPCA SCAR2 213200 Lebanon, France, French
Canadians
Intellectual disability, hypotonia, short
stature, severe phenotype with lactic
academia and ophthalmoplegia,
congenital or infantile onset, cerebellar
atrophy
[94–96]










signs, childhood onset, atrophy of the
cerebellum and pons; allelic to HSP39
[100, 101]




myopia, short stature, infantile to
childhood onset, diffuse cerebral
hypomyelination, cerebellar atrophy,
thin corpus callosum, T2 hypointense
thalamus
[102, 103]
ATX-POLR3B HLD8 614381 Japan, Caucasians, Syria,
African American,
Mediterranean
Intellectual disability, vertical gaze
limitation, hypodontia,
hypogonadotropic hypogonadism,
myopia, mild hyperreflexia, short
stature, infantile to childhood onset,
diffuse cerebral hypomyelination with
partly myelinated internal capsule,
[104, 105]




Alternate nomenclature2 OMIM Geographic specificities Additional clinical clues and
neuroimaging findings
References
cerebellar atrophy, thin corpus




212840 Middle East, Caucasians Hypogonadotropic hypogonadism,
dementia, occasional chorea,
childhood to young adult onset,
cerebellar atrophy, cerebral white
matter anomalies
[106, 107]
SCYL1 SCAR21 616719 European, Middle East, Cuba,
Ashkenazi Jews
Transient episodes of liver failure,
intention tremor, peripheral
sensorimotor neuropathy, mild
cognitive impairment, occasional short
stature, infantile to childhood onset,
cerebellar vermis atrophy
[108, 109]





occasional sensorineural hearing loss,
infantile onset, cerebellar atrophy
[110, 111]
SLC9A1 LIKNS/SCAR19 616291 Turkey, Han Chinese Occasional sensorineural hearing loss,
mild psychomotor delay, infantile to
childhood onset, progressive cerebellar
atrophy
[112, 113]




occasional tremor, infantile to
childhood onset, cerebellar atrophy;
allelic to SCA5
[114, 115]
ATX-STUB1 SCAR16 615768 China, Middle East, Caucasians Pyramidal signs, variable cognitive
impairment, occasional
hypogonadism, variable age at onset,
cerebellar atrophy; allelic to SCA48
[116, 117]
TDP2 SCAR23 616949 Ireland, USA Seizures, developmental delay,
dysmorphism, hypotonia,
hypersomnia, failure to thrive, infantile
to childhood onset, absence of
cerebellar atrophy
[118, 119]
ATX-TPP1 SCAR7 609270 The Netherlands, African
American population
Occasional pyramidal signs, posterior
column involvement, tremor,
square-wave jerks, nystagmus, child-
hood to adolescent onset,
pontocerebellar atrophy; allelic to
CLN2
[120, 121]
HSP/ATX-UCHL1 SPG79 615491 Norway, Turkey Optic atrophy, nystagmus, intention









moderate to severe intellectual
disability, hypotonia, strabismus,
delayed ambulation with occasional
quadripedal gait, seizures, congenital




VPS13D SCAR4 607317 Europe, USA, French
Canadian, Egyptian,
Javanese
Pyramidal signs, axial hypotonia,
oculomotor abnormalities, chorea or
dystonia, cognitive impairment,
infantile to adult onset, cerebellar
atrophy, basal ganglia T2/F
hyperintensity
[126, 127]
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for Friedreich ataxia, ataxia with oculomotor apraxia 1
and 2, and POLG-related disorders. Finally, recessive
ataxia with onset in adulthood is evocative of autosomal
recessive cerebellar ataxia 1 and 3 and spastic paraplegia
7. However, there are large variations in the age at onset of
most of the presented disorders, and Friedreich ataxia is
one of the best examples with some patients presenting
with late-onset (> 25 years of age) or very-late-onset
Friedreich ataxia (> 40 years of age). Clinical signs and
symptoms may provide clues to identify the mutated
gene. Indeed, certain discriminating clinical features or
combinations of neurological symptoms may be helpful
to guide the clinician towards specific genes (Fig. 1 and
Table 1). As one may observe in Fig. 1, none of the auto-
somal recessive ataxias reported up to now presents with a
pure cerebellar phenotype. Even SYNE1-related autoso-
mal recessive cerebellar ataxia 1, which used to be the
prototype of a pure cerebellar phenotype [21], has recent-
ly been reported to be associated with upper and/or lower
motor neuron involvement in 58% of cases, with some
rare patients presenting with a very severe early-onset
neuromuscular phenotype [22]. The presence of motor
neuron involvement, polyneuropathy, extrapyramidal
movement disorders, eye movement abnormalities such
as oculomotor apraxia, intellectual impairment, and asso-
ciated multisystemic involvement may guide the clinician
towards a particular diagnosis. Some clinical syndromes
are particularly evocative of specific disorders.
Multisystemic involvement with sensory loss, muscle
weakness, cardiomyopathy, diabetes, optic atrophy, and
sensorineuronal hearing loss is characteristic of
Friedreich ataxia, which is the prototype of a disorder
associated with mitochondrial dysfunction. Other associ-
ated disorders present with similar features and occasion-
ally epilepsy, retinal involvement, or ophthalmoplegia,
such as POLG-related disorders, autosomal recessive cer-
ebellar ataxia 2, and Marinesco-Sjogren syndrome.
Extrapyramidal involvement with oculomotor apraxia, el-
evated α-fetoprotein, and occasional polyneuropathy are
typical findings of ataxia telangiectasia, ataxia
telangiectasia-like disorder, spinocerebellar ataxia reces-
sive 26, and ataxia with oculomotor apraxia types 1, 2,
and 4. Nevertheless, autosomal recessive ataxias are char-
acterized by important phenotypic variability and signifi-
cant clinical overlap between different pathologies, such
that predicting the mutated gene according to the clinical
phenotype is prone to errors even for ataxia experts [219].
Some laboratory tests may serve as useful biomarkers for
recessive ataxias. Altered levels of vitamin E, α-fetopro-
tein, albumin, coenzyme Q10, cholesterol, cholestanol,
lactate, sex hormones, and gonadotropins have been asso-




Alternate nomenclature2 OMIM Geographic specificities Additional clinical clues and
neuroimaging findings
References
ATX-WDR81 CAMRQ2/DES2 610185 Turkey, Yemen Occasional quadrupedal gait, intellectual
disability, congenital onset, cerebellar
hypoplasia; allelic with Congenital
hydrocephalus type 3 with brain
anomalies
[128, 129]
XRCC1 SCAR26 617633 India, Pakistan Oculomotor apraxia with nystagmus,
peripheral sensorimotor axonal
neuropathy, cognitive impairment,
childhood to adult onset, progressive
cerebellar atrophy
[130, 131]
In part inspired from [3]
1MDS nomenclature: nomenclature proposed by the Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement
Disorders [4] with a phenotypical prefix followed by the gene name. ATX ataxia, HSP hereditary spastic paraplegia,MYC myoclonus
2AOA ataxia with oculomotor apraxia, ARCA autosomal recessive cerebellar ataxia, ARSACS autosomal recessive spastic ataxia of Charlevoix-
Saguenay, AT ataxia telangiectasia, ATLD ataxia telangiectasia-like disorder, AVED ataxia with vitamin E deficiency, BNS Boucher-Neuhäuser syn-
drome, CA Cayman ataxia, CAMRQ cerebellar ataxia mental retardation with or without quadrupedal locomotion, DCMA dilated cardiomyopathy with
ataxia, DES disequilibrium syndrome, EAOH early-onset ataxia with oculomotor apraxia and hypoalbuminemia, FRDA Friedreich ataxia,GHS Gordon
Holmes syndrome,HLD hypomyelinating leukodystrophy, IOSCA infantile onset spinocerebellar ataxia, LIKNS Lichtenstein-Knorr syndrome,MGCA5
3-methyglutaconic aciduria type 5, MIRAS mitochondrial recessive ataxia syndrome, MC4D mitochondrial complex 4 deficiency, MSS Marinesco-
Sjogren syndrome, MTDPS7 mitochondrial DNA depletion syndrome 7, NBIA neurodegeneration with brain iron accumulation, OMCS Oliver
McFarlane syndrome, PBD peroxisome biogenesis disorder, PEOA3 progressive external ophthalmoplegia with mitochondrial DNA deletions, auto-
somal dominant 3, PHARC polyneuropathy hearing loss ataxia retinitis pigmentosa and cataract, SANDO sensory ataxic neuropathy with dysarthria and
ophthalmoparesis, SCAE spinocerebellar ataxia with epilepsy, SCAN1 spinocerebellar ataxia with axonal neuropathy 1, SCAR spinocerebellar ataxia
autosomal recessive, SeSAME seizures sensorineural deafness ataxia mental retardation and electrolyte imbalance, SPAX spastic ataxia, SPG spastic
paraplegia, UMN upper motor neuron, ZSD Zellweger spectrum disorder
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Table 2 Other metabolic or complex autosomal recessive disorders that have ataxia as an associated feature
MDS nomenclature1 or gene
name

















Developmental delay, ataxia, hypotonia, neonatal breathing
abnormalities, intellectual disability, nephronophthisis,
congenital onset, agenesis of the cerebellar vermis with molar
tooth sign; in COACH syndrome, associated with ocular





603147 Developmental delay, intellectual disability, language dysfunction,
hypotonia, hyporeflexia, autistic behavior and hallucinations,
infantile to childhood onset, T2 hypersignal in globi pallidi
[134, 135]
ATX-ALG6 CDG1c 603147 Developmental delay, hypotonia, seizures, protein-losing
enteropathy, psychiatric manifestations, nystagmus, strabismus,
failure to thrive, dysmorphic features, neonatal to infantile onset,
occasional brain atrophy
[136, 137]
DYT/ATX-ATP7B Wilson disease 277900 Tremor, dystonia, parkinsonism, choreoathetosis, liver disease,
psychiatric involvement, Kayser-Fleischer rings, childhood to
adult onset, T2 hypersignal in basal ganglia or brainstem
[138]
ATP8A2 CAMRQ4 615268 Global development delay, cognitive impairment, microcephaly,
ataxia or quadrupedal gait, choreoathetoid movement, congenital
onset, cerebellar and cerebral atrophy or delay in myelination
[139, 140]
HSP/ATX-B4GALNT1 SPG26 609195 Pyramidal signs, amyotrophy, progressive hyporeflexia, cognitive
impairment, axonal peripheral neuropathy, occasional cerebellar
ataxia and extrapyramidal signs, scoliosis, childhood to teenage
onset, cerebral cortical atrophy, T2/F white matter hyperintensity
[141]
ATX-BTD Biotinidase deficiency 253260 Seizures, hypotonia, developmental delay, optic atrophy,
sensorineural hearing loss, skin rash, alopecia,
hepatosplenomegaly, optic atrophy, exacerbation during
infections, infantile to childhood onset, white matter anomalies
including delayed demyelination
[142, 143]
MYC-CLN5 CLN 256731 Myoclonic epilepsy, psychomotor retardation or regression, ataxia,
visual loss, ataxia, infantile to adult onset, cerebellar and cortical
atrophy
[144]
NBIA/DYT/PARK-CP Aceruloplasminemia 604290 Diabetes, dementia, parkinsonism, dystonia, cerebellar ataxia,
retinal degeneration, involuntary movements, anemia, low serum
and urinary copper, adult onset, decreased signal intensity in
thalamus, basal ganglia and dentate nucleus
[145]
MYC/ATX-CSTB1 Unverricht and Lundborg
disease/EPM1
254800 Stimulus-sensitive and action-sensitive myoclonus, tonic-clonic
generalized seizures, mild cerebellar ataxia, cognitive








603896 Cerebellar ataxia with spasticity, clinical deterioration following
head trauma, febrile illness or surgery, infantile to adult onset,
symmetric and diffusely abnormal cerebral white matter that




Lafora disease 607566 Myoclonus, generalized tonic-clonic seizures, occipital seizures,
headaches, behavioral deterioration, rapidly progressive
dementia, cerebellar ataxia, spasticity, adolescent onset, normal





278760 Photosensitivity, solar lentigine growth retardation, microcephaly,
ataxia, chorea, cognitive impairment, adolescent to adult onset,
cerebellar and brainstem atrophy
[151, 152]
HSP/ATX/NBIA-FA2H SPG35/FAHN 612319 Spastic paraparesis, pyramidal signs, dystonia, ataxia, dysarthria,
optic atrophy, seizures, cognitive impairment, childhood to
adolescent onset, T2 subcortical and periventricular white matter
hyperintensity, atrophy of the cerebellum and brainstem
[153]
ATX/HSP-FOLR1 Neurodegeneration due to
cerebral folate transport
deficiency
613068 Developmental regression, hypotonia, myoclonic, tonic or astatic
seizures, cerebellar ataxia, chorea, tremor, autism spectrum
disorder, occasional pyramidal signs, infantile onset, delayed
myelination in cerebral white matter, cerebellar atrophy
[154, 155]
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Table 2 (continued)
MDS nomenclature1 or gene
name
Alternate nomenclature2 OMIM Additional clinical clues References
HSP/ATX-GAN1 Giant axonal neuropathy 1 256850 Peripheral sensorimotor neuropathy, weakness, amyotrophy,
areflexia, pes cavus, typical frizzly hair, ataxia, nystagmus,
pyramidal signs, seizures, cognitive impairment, childhood onset,
cerebellar or cerebral white matter T2 hypersignal
[156, 157]
DYT/PARK-GLB1 GM1 gangliosidosis type II 230600 Developmental regression in childhood with gait disorder and
cognitive impairment, dystonia, hepatosplenomegaly, ataxia,
skeletal dysplasia, cardiomyopathy, infantile to childhood onset,
progressive diffuse brain atrophy
[158, 159]
ATX/HSP-HEXA Tay-Sachs disease 272800 Infantile form with weakness, motor regression, startle reaction,
myoclonic jerks, decreased attentiveness, cherry red spots,
dementia, blindness. Juvenile form with ataxia, dysarthria,
incoordination; adult form with ALS-like symptomatology
[160, 161]




233400 Sensorineural hearing loss, ovarian dysfunction, ataxia, dysarthria,
dysmetria, hyperreflexia, cognitive impairment, sensory
neuropathy, childhood onset, cerebellar atrophy
[163, 164]
HSP-KIAA1840 SPG11 604360 Spasticity, ataxia, cognitive impairment, sensorimotor neuropathy,
childhood or teenage onset, thin corpus callosum, signal
abnormalities in cervical cord
[165, 166]
MYC/ATX-KCTD7 EPM3/CLN14 611726 Multifocal myoclonic seizures, status myoclonus, motor and
language regression, intellectual disability, cerebellar ataxia,
infantile onset, diffuse cerebral and cerebellar atrophy, T2
periventricular white matter hyperintensity
[167, 168]
ATX-MAN2B1 Alpha-mannosidosis 248500 Dysmorphism, skeletal abnormalities, visceromegaly, sensorineural
hearing loss, immunodeficiency, cognitive impairment,
psychosis, ataxia, prenatal to adult onset, cerebellar atrophy,





604004 Macrocephaly, initial radiological-clinical discrepancy, eventual
motor regression, ataxia, spasticity, epilepsy, cognitive decline,
infantile onset, diffuse supratentorial white matter signal anoma-
lies
[170]
ATX-MSTO1 MMYAT 617619 Myalgia, proximal muscle weakness, psychiatric manifestations,
developmental delay, tremor, dysmetria, pigmentary retinopathy,
growth retardation, neonatal to childhood onset, cerebellar
atrophy
[171, 172]
MTTP Abetalipoproteinemia 200100 Fat malabsorption symptoms, hypocholesterolemia,
hypotriglyceridemia, acanthocytosis, sensory loss, hyporeflexia,
ataxia, neonatal onset, absence of cerebellar atrophy
[173]
MYC/ATX-NEU1 Neuraminidase deficiency
or sialidosis type I and II
256550 Myoclonic epilepsy, visual impairment, cherry red spots, ataxia,
hyperreflexia, severe phenotype with dysmorphic features,
dysostosis multiplex, hepatomegaly, developmental delay,
increased urinary bound sialic acid, variable age at onset, diffuse





617560 Nystagmus, developmental delay, hypotonia followed by rapidly
progressive spasticity, weakness, dystonia, dysphagia, ataxia,
visual impairment, infantile to childhood onset, brain




Niemann-Pick type C 257220
607625
Vertical supranuclear ophthalmoplegia, gelastic cataplexy,
premature cognitive decline, dystonia, hepatosplenomegaly,
respiratory failure, seizures, psychiatric features, neonatal to adult
onset, variable cerebellar or cerebral atrophy
[178–180]
OPA1 Behr syndrome 210000 Optic atrophy, pyramidal signs, sensorimotor peripheral neuropathy,
cerebellar ataxia, developmental delay, gastrointestinal
symptoms, infantile or childhood onset, cerebellar atrophy; allelic




614867 Hypotonia, seizures, inability to feed, ataxia, hyporeflexia, slow
saccades, sensorimotor neuropathy, childhood to adult onset,
cerebellar atrophy
[183, 184]
ATX-PEX7 PBD9B 614879 Retinitis pigmentosa, polyneuropathy, ataxia, anosmia, pes cavus,
skeletal abnormalities, ichthyosis, hearing loss, cataracts,
[185]
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Table 2 (continued)
MDS nomenclature1 or gene
name
Alternate nomenclature2 OMIM Additional clinical clues References
cardiomyopathy, elevated phytanic acid, childhood or teenage
onset, absence of cerebellar atrophy
ATX-PHYH Refsum disease 266500 Retinitis pigmentosa, polyneuropathy, increased CSF protein,
anosmia, sensorineural hearing loss, ichthyosis, ataxia, teenage
onset, elevated serum phytanic acid, absence of cerebellar
atrophy
[186]
NBIA/DYT/PARK-PLA2G6 NBIA 2A 256600 Psychomotor retardation or regression, hypotonia followed by
spastic quadriparesis, ataxia, strabismus, nystagmus, infantile to
teenage onset, cerebellar atrophy and variable iron accumulation
in globi pallidi with associated T2 hypointensity
[187, 188]
ATX-PMM2 CDG 1a 212065 Intellectual disability, axial hypotonia, visceral involvement with
feeding difficulties and cardiac involvement, dysmorphic
features, cerebellar ataxia, strabismus, peripheral neuropathy,
retinitis pigmentosa, skeletal abnormalities, infantile to adult




614386 Seizures, paroxysmal nonkinesigenic dyskinesia, paroxysmal
vertigo, episodic ataxia, hemiplegic migraine, rare progressive
ataxia, infantile to childhood onset, occasional cerebellar atrophy
[191, 192]
ATX-PTRH2 IMNEPD 616263 Developmental delay, intellectual disability, hypotonia, muscular
weakness, demyelinating sensorimotor neuropathy,
dysmorphism, ataxia, microcephaly, growth retardation,
sensorineural deafness, pancreatic insufficiency, infantile onset,
variable cerebellar atrophy
[193, 194]
SEPSECS PCH 2D 613811 Developmental delay, intellectual disability, hypotonia, nystagmus,
microcephaly, seizure, ataxia, spasticity, chorea, congenital to
infantile onset, cerebellar and cerebral atrophy, thinning of corpus
callosum
[195, 196]
ATX-SLC17A5 Sialic acid storage diseases 604369
269920
Severe neonatal phenotype with ascites, failure to thrive and early
death. Milder infantile phenotype with hypotonia, cerebellar
ataxia and intellectual disability, infantile to adult onset,
hypomyelination, cerebellar atrophy
[197–199]
SLC2A1 GLUT1 deficiency 606777 Epileptic encephalopathy, psychomotor retardation, hypotonia,
dystonia, microcephaly, ataxia, spasticity, seizures, infantile




Sensorimotor neuropathy, optic atrophy, blindness, sensorineural
hearing loss, respiratory insufficiency, bulbar involvement,
childhood onset, absence of cerebellar atrophy; ataxia is on a
spectrum between Brown-Vialetto-Van Laere syndrome type 2
and SCAR3
[202–204]
SLC6A19 Hartnup disorder 234500 Transient manifestations of pellagra, cerebellar ataxia, psychosis,
nystagmus and ophthalmoparesis, cognitive impairment, amino
aciduria, early onset
[205]
SLC25A46 CMT6B 616505 Optic atrophy, blindness, severe sensorimotor neuropathy,
hyporeflexia, amyotrophy, pes cavus, sensory loss in lower limbs,
sensitive and cerebellar ataxia, nystagmus, divergent strabismus,
neonatal to childhood onset, cerebellar and brain atrophy, T2
hyperintensity in cerebellar white matter
[206, 207]
ATX-SRD5A3 CDG 1q 612379 Hypotonia, intellectual disability, optic nerve atrophy, nystagmus,
ocular colobomas, ichthyosis, palmoplantar keratodermia, mild
ataxia, congenital to childhood onset, cerebellar vermis
hypoplasia
[208, 209]
ATX-TTC19 MC3DN2 615157 Muscular hypotonia progressing to spasticity, developmental delay,
neurological regression with loss of language and ambulation,
cognitive regression, rapid evolution, axonal motor neuropathy,
psychiatric features, infantile to adult onset, cerebral and
cerebellar atrophy, T2 hypersignal in basal ganglia, bilateral
inferior olive involvement
[210–212]
ATX-WDR73 GMS/SCAR5 251300 Intellectual disability, nephrotic syndrome, microcephaly,
hypotonia, epilepsy, optic atrophy, skin abnormalities, infantile to
childhood onset, cerebellar and cerebral atrophy
[213, 214]
WFS1 Wolfram syndrome 222300 [215]
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immunoglobulins, very long chain fatty acids, and hexos-
aminidasemay be relevant according to clinical suspicion.
5. Once the clinical assessment is complete, genetic test-
ing is indicated to confirm the mutated gene or allow a
more specific diagnosis if the clinical picture is non-
specific. Initial testing should include searching for the
Friedreich ataxia-associated trinucleotide repeat ex-
pansion in the FXN gene considering the high preva-
lence of this mutation, its incomplete coverage through
the next-generation sequencing methods [1], and the
heterogeneous clinical phenotype. Searching for a
FXN repeat expansion can be done with frataxin pro-
tein analysis or gene analysis with Southern blot or
PCR. Moreover, clinicians may consider testing for
another specific gene through Sanger sequencing or
multiplex ligation-dependent probe amplification
(MLPA) if the clinical and paraclinical data are highly
evocative of a particular disorder, if there is a con-
firmed mutation in a relative or in isolated populations
where selected disorders are highly prevalent. Finally,
a panel for the dominantly inherited CAG-repeat ex-
pansion spinocerebellar ataxias may also be considered
as part of the initial assessment if family history is
inconclusive regarding the mode of inheritance and
considering the high prevalence of these mutations
and their incomplete coverage through the next-
generation sequencing methods [1].
6. If single gene testing does not provide a molecular diag-
nosis, one should consider the high-throughput NGS
methods either with a multigene panel, whole exome
sequencing, or whole genome sequencing. Several studies
have demonstrated the efficacy and cost efficiency of
multigene panels [220], targeted exome sequencing
[219, 221], or whole exome sequencing [222, 223], with
a diagnostic yield varying between 18 and 80%. The
highest yield is obtained for patients with early-onset atax-
ia and positive family history and consanguinity among
parents. NGS panels allow for better coverage of included
genes and reduce the volume of genetic variants that are
unrelated to the clinical phenotype, while exome sequenc-
ing may reveal mutations in genes that were not previous-
ly known to be associated with ataxia [1]. Whole genome
sequencing may be considered in selected cases with ap-
propriate genetic counseling, but its diagnostic yield is
uncertain [224]. Once genetic testing is completed and a
pathogenic mutation has been identified, it is of primary
importance to provide specialized genetic counseling for
the patient and his or her relatives along with symptom
management and disease treatment when available.
Figure 2 presents a graphical summary of the proposed
clinical approach.
Pathophysiological Mechanisms Underlying
Autosomal Recessive Cerebellar Ataxias
The importance of a proper recessive ataxia classification goes
beyond the clinical diagnosis perspective. Autosomal reces-
sive ataxias can be regrouped according to the deficient cellu-
lar and metabolic pathways involved, which provide a better
understanding of cerebellar physiology and of its selective
vulnerability to certain metabolic defects. This is also essential
Table 2 (continued)
MDS nomenclature1 or gene
name
Alternate nomenclature2 OMIM Additional clinical clues References
Diabetes mellitus, optic atrophy, diabetes insipidus, deafness, renal
abnormalities, ataxia, intellectual disability, psychiatric features,
childhood to adolescent onset, generalized brain and cerebellar
atrophy
WWOX SCAR12 614322 Tonic-clonic epilepsy, intellectual disability, spasticity, neonatal to
childhood onset, variable cerebellar or cerebral atrophy,
phenotypic spectrum with infantile epileptic encephalopathy
associated with psychomotor retardation and growth retardation
[216, 217]
1MDS nomenclature: nomenclature proposed by the Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement
Disorders [4] with a phenotypical prefix followed by the gene name. ATX ataxia, DYT dystonia, HSP hereditary spastic paraplegia, MYC myoclonus,
NBIA neurodegeneration with brain iron accumulation, PARK Parkinsonism
2ALS amyotrophic lateral sclerosis, BVVLS2 Brown-Vialetto-Van Laere syndrome type 2, CAMRQ cerebellar ataxia mental retardation with or without
quadrupedal locomotion, CDG congenital disorder of glycosylation, CLN neuronal ceroid lipofuscinosis, CMT Charcot-Marie-Tooth, COACH cerebel-
lar vermis hypoplasia, oligophrenia, congenital ataxia, ocular coloboma, and hepatic fibrosis, EPM progressive myoclonic epilepsy, FAHN fatty acid
hydroxylase-associated neurodegeneration, GMS Galloway-Mowat syndrome, IMNEPD infantile-onset multisystem neurologic, endocrine, and pan-
creatic disease,MC3DN2 mitochondrial complex III deficiency, nuclear type 2,MMYAT mitochondrial myopathy and ataxia, NBIA neurodegeneration
with brain iron accumulation, PBD peroxisome biogenesis disorder, PCH pontocerebellar hypoplasia, SCAR spinocerebellar ataxia autosomal recessive,
SPAX spastic ataxia, SPG spastic paraplegia
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from a therapeutic perspective, as disorders that belong to the
same metabolic pathway may respond to the same treatment
options, indicating potential for drug repurposing. Figure 3
presents a pathophysiological classification of autosomal re-
cessive ataxias. Certain genes are presented more than once
since some proteins are involved in several metabolic path-
ways or may interfere with other cellular processes as they
accumulate in neurons or glial cells. Table 3 presents a more
detailed listing of the pathogenic pathways involved along
with relevant references.
Certain pathways are predominantly involved, notably mi-
tochondrial dysfunction, which may result from abnormal mi-
tochondrial DNA maintenance with progressive mutagenesis,
defective mitochondrial protein synthesis and quality control,
increased levels of reactive oxygen species and oxidative
stress, deficient coenzymeQ10metabolism, alteredmitochon-
drial dynamics, defective mitochondrial chain assembly, or
abnormal mitochondrial RNA maturation and processing
(Table 3). Interestingly, many of the disorders caused by mi-
tochondrial dysfunction also present with a mitochondrial
clinical syndrome as shown in Fig. 1. Disorders of DNA repair
mechanisms are also common, with double-strand break re-
pair pathway or single-strand break repair complexes predom-
inantly involved. Pathogenic mutations in these genes are also
associated with a susceptibility to ionizing radiations and pre-
disposition for cancers, but the neurological syndrome is char-
acterized by cerebellar involvement and extrapyramidal
movement disorders. It remains debated whether defective
DNA repair is the main pathogenic mechanism causing the
neurological phenotype [230], but the fact that several
interacting genes in this pathway are involved in degenerative
cerebellar ataxias suggests that the cerebellum has a peculiar
susceptibility to DNAdamage for which the underlyingmech-
anism is not understood. Finally, altered synaptic morphology
or synaptic dysfunction of Purkinje cells (PC) is frequently
involved in recessive ataxias and is associated with aberrant
Fig. 1 Clinical classification of autosomal recessive ataxias. The gene
associated with each primary recessive ataxia is classified according to
the most frequent clinical syndrome described for this disorder. Note that
some disorders havemore complex or variable phenotypes and are placed
in the overlapping areas between two categories. Genes presented in
larger font represent the most prevalent ataxias
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morphology at the PC/parallel fiber synapse, impaired den-
dritic architecture, or dysregulation of glutamate transmission.
Other disorders have been implicated in synaptic dysfunction
through indirect evidence, for example, SLC9A1, which lo-
calizes in presynaptic terminals and is involved in the modu-
lation of synaptic activity [254, 275]. Of interest, many of
these disorders are characterized by significant cognitive im-
pairment that goes beyond what is expected in the cerebellar
cognitive-affective syndrome and cause intellectual disability,
developmental delay, or dementia, highlighting the impor-
tance of synaptogenesis in cognitive development.
Discussion
We present a new clinical classification of autosomal recessive
ataxias in parallel with a pathophysiological classification.
The objective of this classification is to provide a tool for
clinicians and researchers that facilitates the understanding
of this complex group of disorders and defines this field of
research. This work is based on the results of our systematic
scoping review of the literature [3]. We updated this literature
review and regrouped a panel of 12 international ataxia ex-
perts to build a consensus on the definition and classification
of cerebellar ataxias. The task force vision is that a
classification goes beyond the listing of disorders and must
organize diseases in a way that allows better understanding
and clinical mastery of this group of disorders. Hence, we
proposed a clinical classification along with a pathophysiolog-
ical classification, which enabled us to observe that there is
significant overlap between these two classifications,
highlighting how clinical presentation is in some cases a good
projection of the underlying biochemical defect. This has po-
tential applications from bench to bedside since treatments
that address a specific pathogenic pathway may have thera-
peutic potential in all disorders in which this pathway is af-
fected. The clinical classification is presented along with a
structured clinical approach to a patient presenting with ataxia,
which is intended as a clinical tool for expert and nonexpert
clinicians. Despite the increasing accessibility of the NGS
techniques, there remains a critical place for clinical judgment
in the prescription of genetic tests and interpretation of results,
taking into account the technical limitations and risk of finding
variants of unknown significance. Recently, Renaud and col-
leagues published the results of a diagnostic algorithm for
recessive ataxias that integrates 124 clinical features to pro-
pose three potential diagnoses among a list of 67 recessive
disorders that may present with ataxia [285]. This is a very
promising tool, but its pragmatic impact on molecular testing
strategy, final diagnostic rate, patient management, or time
efficiency remains to be validated. In the meantime, it is es-
sential for clinicians to be at ease with a general approach to
recessive ataxias with the NGS techniques often permitting
molecular diagnosis when the clinical picture is nonspecific.
One of the major strengths of this classification proposal is
that it is based on a consensus from a panel of international
ataxia experts, thereby ensuring a proper representation of
regional differences in the prevalence and clinical approach
to ataxias. Moreover, the literature search was based on a
systematic scoping review of the literature whose methodolo-
gy has been published before and which permitted an unbi-
ased appraisal of all potentially relevant articles. Nevertheless,
there are some limitations to this classification proposal that
are inherent to classifying a group of diseases that evolves
very rapidly and that is highly heterogeneous. First, as new
evidence emerges regarding the identification of novel ataxia-
associated genes and as new phenotypes are described for
previously described disorders, this classification will need
to be updated. This was highlighted by the significant addi-
tions to the list of primary recessive ataxias since the original
systematic review was conducted in 2016. Indeed, many new
genes and new phenotypes of previously described genes have
been reported in only 2 years, which suggests that there is a
need for periodic updates to the present classification or an
online resource. Moreover, several decisions were made in the
elaboration of this classification regarding general orientation,
purpose of a classification, inclusion of specific disorders, and
classification categories. The lists presented here offer in our
Fig. 2 Graphical summary of the clinical approach to a patient presenting
with ataxia
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opinion the best compromise between synthesis and exhaus-
tiveness for the expert and nonexpert clinician.
Compared with a previously published report by the
Movement Disorders Society Task Force [4], we decided to
exclude disorders in which cerebellar involvement is a minor
or late finding in a complex multisystem phenotype or disor-
ders that are already classified on their own, such as genes
associated with Joubert syndrome. The objective was to
Fig. 3 Pathophysiological classification of autosomal recessive ataxias.
A Purkinje cell is depicted along with a granule cell and parallel fibers.
Subcellular organelles and structures are represented graphically. Each
gene is classified at one or more subcellular localizations according to
the different metabolic pathways involved
Cerebellum (2019) 18:1098 1125–1113
identify the core disorders that are involved in autosomal re-
cessive ataxias in order to define this field of research and
build a classification that would be accessible for all clini-
cians. Indeed, with the progressive advent of affordable
NGS diagnostic testing, we believe that it is most important
for clinicians to be at ease with one classification and familiar
with the most frequent disorders in their unique ethnical and
clinical context. Disorders in which ataxia has been reported
as a rare or late finding should be included in large NGS
testing strategies, but in our opinion should not be categorized
as primary ataxias per se. From this perspective, our classifi-
cation complements the proposal by the Movement Disorders
Society Task Force.
There remain some important challenges to be addressed in
the field of autosomal recessive ataxias. First, the issue of a
proper nomenclature system has been much debated.
Recently, the Movement Disorders Society Task Force pro-
posed a revised naming system based on an ataxia prefix as-
sociated with the gene name [4]; this was part of a larger effort
to revise the nomenclature of all genetic movement disorders.
Table 3 Detailed pathogenic mechanisms involved in autosomal recessive cerebellar ataxias
Pathophysiological mechanism Genes involved References
Mitochondrial defect Mitochondrial DNA maintenance PNKP, POLG, TWNK [225–227]
Mitochondrial protein synthesis or
quality control
AFG3L2, PMPCA, SPG7 [94, 228, 229]
Increased reactive oxygen species and
oxidative stress
ATM, FXN, TTPA [230–233]
Coenzyme Q10 metabolism APTX, COQ8A [234, 235]
Altered mitochondrial dynamics SACS, VPS13D [127, 236–238]
Mitochondrial respiratory chain
assembly
COA7, COX20 [54, 55]
Mitochondrial RNA maturation and
processing
DARS2, MTPAP [91, 239, 240]
Others DNAJC19, L2HGDH, STUB1 [241–243]
DNA break repair
dysfunction
Double-strand break repair ATM, MRE11A, SETX, TDP2 [118, 230, 244, 245]
Single-strand break repair APTX, PNKP, XRCC1 [130, 225]
RNA transcription or processing defect CWF19L1, POLR3A, POLR3B, SETX [57, 104, 246]
Synaptic dysfunction Aberrant morphology at the PC/parallel
fibers synapse
CA8, CAPN1, GRID2, ITPR1 [50, 247–249]
Impaired dendritic architecture SPTBN2, SYNE1 (MF/CGN synapse) [250, 251]
Dysregulation of glutamate transmission ATCAY, GRM1 [252, 253]
Others GOSR2, RNF216, SLC9A1, UCHL1 [254–257]
Abnormal cytoskeleton architecture SACS, SYNE1 [251, 258]
Abnormal protein folding or quality control SACS, SIL1, STUB1 [259–261]
Golgi apparatus dysfunction COQ8A, GOSR2, SCYL1 [235, 255, 262]
Calcium homeostasis dysregulation AFG3L2, ANO10, CA8, ITPR1, SPG7 [79, 247, 263–266]
Lysosomal dysfunction GRN, TPP1 [267, 268]
Disrupted autophagy SNX14, VPS13D [238, 269]
Defective ubiquitin-proteasome pathway RNF216, STUB1, UCHL1 [256, 257, 261]
Altered intracellular trafficking GOSR2, SCYL1, SPTBN2, SYNE1, TTPA [250, 251, 255, 262,
270]
Altered lipid metabolism ABHD12, CYP27A1, CYP7B1, DNAJC19, GBA2,
PNPLA6, SNX14, TTPA
[60, 233, 241, 269,
271–274]
Axonal dysfunction DARS2, GJC2, KCNJ10, PNPLA6, SLC9A1 [239, 274–277]
Abnormal myelin structure or composition ABHD12, CLCN2, GJC2, KCNJ10, KIF1C, L2HGDH,
POLR3A, POLR3B
[242, 276–281]
Disrupted intrinsic Purkinje cell firing SACS, SPTBN2 [250, 282]
Abnormal cellular stress response GDAP2 [68]
Peroxisome dysfunction PEX10 [92]
Impaired mitosis WDR81 [283]
Abnormal neuronal migration VLDLR [284]
CGN cerebellar granule neuron, MF mossy fiber, PC Purkinje cell
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This system overcomes the limitations of the numbered no-
menclature, notably unconfirmed genes, and erroneously at-
tributed phenotypes, but its ease of use by nonexperts and
patients remains uncertain. Moreover, some disorders were
assigned as many as three phenotypic prefixes while some
other disorders that are among the most prevalent causes of
recessive ataxia, such as POLG, were not assigned an ataxia
prefix. Hence, there remains a debate concerning the attribu-
tion of prefixes and the integration of this naming system with
other fields in neurology and other specialties as many genes
involved in ataxia have very complex multisystem pheno-
types. Finally, one of the most important challenges in this
field of orphan diseases is to develop targeted treatment strat-
egies that address the pathogenic mechanism underlying
symptom progression. To this end, we believe that identifying
common pathophysiological pathways may provide an oppor-
tunity for drug repurposing or enlarge the number of patients
that are admissible for drug trials in order to find treatments for
these rare but debilitating diseases.
Conclusion or Summary
We present a clinical and a pathophysiological classification
of autosomal recessive cerebellar ataxias along with a clinical
approach to a patient presenting with ataxia. This classifica-
tion is the result of a consensus among a panel of international
experts, and it promotes a unified understanding of autosomal
recessive cerebellar disorders for clinicians and researchers.
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